BRPI0514407A - forma ii de polimorfo de rapamicina, processos para preparar a forma ii do polimorfo de rapaminicina, e a forma i do polimorfo de rapamicina, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica - Google Patents

forma ii de polimorfo de rapamicina, processos para preparar a forma ii do polimorfo de rapaminicina, e a forma i do polimorfo de rapamicina, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica

Info

Publication number
BRPI0514407A
BRPI0514407A BRPI0514407-8A BRPI0514407A BRPI0514407A BR PI0514407 A BRPI0514407 A BR PI0514407A BR PI0514407 A BRPI0514407 A BR PI0514407A BR PI0514407 A BRPI0514407 A BR PI0514407A
Authority
BR
Brazil
Prior art keywords
polymorph form
pharmaceutical composition
preparing
rapamycin polymorph
rapamycin
Prior art date
Application number
BRPI0514407-8A
Other languages
English (en)
Inventor
Tianmin Zhu
Mahdi B Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35431373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514407(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0514407A publication Critical patent/BRPI0514407A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

FORMA II DE POLIMORFO DE RAPAMICINA, PROCESSOS PARA PREPARAR A FORMA II DO POLIMORFO DE RAPAMICINA, E A FORMA I DO POLIMORFO DE RAPAMICINA, COMPOSIçãO FARMACêUTICA, KIT, E, MéTODO PARA PREPARAR UMA COMPOSIçãO FARMACêUTICA A presente invenção provê a Forma II do polimorfo de rapamicina. Esta invenção refere-se também a processos para a preparação da Forma II do polimorfo de rapamicina e a composições farmacêuticas, que incluem a Forma H do polimorfo de rapamicina.
BRPI0514407-8A 2004-08-20 2005-08-18 forma ii de polimorfo de rapamicina, processos para preparar a forma ii do polimorfo de rapaminicina, e a forma i do polimorfo de rapamicina, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica BRPI0514407A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60309604P 2004-08-20 2004-08-20
PCT/US2005/029364 WO2006023627A1 (en) 2004-08-20 2005-08-18 Rapamycin polymorph ii and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0514407A true BRPI0514407A (pt) 2008-06-10

Family

ID=35431373

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514407-8A BRPI0514407A (pt) 2004-08-20 2005-08-18 forma ii de polimorfo de rapamicina, processos para preparar a forma ii do polimorfo de rapaminicina, e a forma i do polimorfo de rapamicina, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica

Country Status (22)

Country Link
US (1) US7282505B2 (pt)
EP (1) EP1781671A1 (pt)
JP (1) JP2008510710A (pt)
KR (1) KR20070051863A (pt)
CN (1) CN101039948A (pt)
AR (1) AR050374A1 (pt)
AU (1) AU2005277407A1 (pt)
BR (1) BRPI0514407A (pt)
CA (1) CA2575887A1 (pt)
CR (1) CR8929A (pt)
EC (1) ECSP077268A (pt)
GT (1) GT200500223A (pt)
IL (1) IL181170A0 (pt)
MX (1) MX2007002044A (pt)
NO (1) NO20071050L (pt)
PA (1) PA8642501A1 (pt)
PE (1) PE20060649A1 (pt)
RU (1) RU2007104518A (pt)
SV (1) SV2006002201A (pt)
TW (1) TW200608973A (pt)
WO (1) WO2006023627A1 (pt)
ZA (1) ZA200701453B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
KR20060085246A (ko) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
JP2010500286A (ja) * 2006-07-25 2010-01-07 アボット・ラボラトリーズ 結晶形態のラパマイシン類似体
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US8486926B2 (en) * 2006-11-17 2013-07-16 Harbor Therapeutics, Inc. Steroid tetrol solid state forms
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
CN102282457A (zh) * 2009-01-21 2011-12-14 拜康有限公司 确定西罗莫司稳定性的方法和制备其稳定形式的工艺
WO2010086863A2 (en) 2009-02-02 2010-08-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Crystalline drug-containing coatings
US20120252834A1 (en) * 2009-08-05 2012-10-04 The Government Of United States, As Represented By The Secretary Of The Army Novel use and method of rapamycin to treat toxic shock
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20140343128A1 (en) 2011-11-15 2014-11-20 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2 - Signal Transducer and Activator of Transcription 5 pathway
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
JP6529012B2 (ja) 2013-10-08 2019-06-12 エイアイ・セラピューティクス・インコーポレーテッド リンパ脈管筋腫症の処置のためのラパマイシン
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
MX2016010373A (es) * 2014-02-11 2016-11-30 Lam Therapeutics Inc Rapamicina para el tratamiento de linfangioleiomiomatosis.
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
RU2732908C2 (ru) 2014-10-07 2020-09-24 ЭйАй ТЕРАПЬЮТИКС, ИНК. Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
CN106478663A (zh) * 2015-08-26 2017-03-08 博瑞生物医药（苏州）股份有限公司 一种依维莫司的干燥方法
US20210154372A1 (en) 2017-05-15 2021-05-27 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物
EP3880266B1 (en) 2018-11-14 2025-05-07 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
EP3952937A1 (en) 2019-04-08 2022-02-16 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
UA41884C2 (uk) * 1993-11-05 2001-10-15 Амерікан Хоум Продактс Корпорейшн Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів

Also Published As

Publication number Publication date
PE20060649A1 (es) 2006-08-10
RU2007104518A (ru) 2008-09-27
SV2006002201A (es) 2006-05-09
ZA200701453B (en) 2010-08-25
GT200500223A (es) 2006-03-09
JP2008510710A (ja) 2008-04-10
EP1781671A1 (en) 2007-05-09
CA2575887A1 (en) 2006-03-02
PA8642501A1 (es) 2006-05-16
KR20070051863A (ko) 2007-05-18
CN101039948A (zh) 2007-09-19
MX2007002044A (es) 2007-03-29
WO2006023627A1 (en) 2006-03-02
CR8929A (es) 2007-08-28
IL181170A0 (en) 2007-07-04
ECSP077268A (es) 2007-03-29
NO20071050L (no) 2007-05-15
AR050374A1 (es) 2006-10-18
US7282505B2 (en) 2007-10-16
TW200608973A (en) 2006-03-16
US20060040971A1 (en) 2006-02-23
AU2005277407A1 (en) 2006-03-02
WO2006023627A8 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
BRPI0514407A (pt) forma ii de polimorfo de rapamicina, processos para preparar a forma ii do polimorfo de rapaminicina, e a forma i do polimorfo de rapamicina, composição farmacêutica, kit, e, método para preparar uma composição farmacêutica
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
BRPI0520870B8 (pt) compostos intermediários para a preparação de alfa-mercaptoacetanilidas de s-triazolila
BRPI0512347A (pt) preparação da pregabalina e compostos relacionados
ATE528989T1 (de) Kristalline feste rasagilin-base
BRPI0815321A2 (pt) "composição, plataforma, kit uso de uma composição, método de diagnóstico, método de manufatura da composição, método de manufatura da plataforma, método de manufatura do kit"
WO2007127834A3 (en) Compositions and methods of preparation thereof
HN2006011218A (es) Composiciones de tigeciclina y métodos de preparación
WO2008127646A3 (en) Transaminase-based processes for preparation of pregabalin
EA200900282A1 (ru) Применение полиолов для получения устойчивых полиморфных форм рифаксимина
WO2009067674A3 (en) Polymorphs of sunitinib base and processes for preparation thereof
IL184714A0 (en) Fast wet-massing method for the preparation of calcium-containing compositions
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
EP1938842A4 (en) METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
PA8781501A1 (es) Formulacion de pasireotida
BRPI0913297B8 (pt) composição farmacêutica estabilizada
EP1969940A3 (en) Nematicidal compositions
CR9257A (es) Polimorfo cci-779 y uso del mismo
GT200500130A (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
WO2007100668A3 (en) Antidepressant prodrugs
GT200500340A (es) Derivados de octahidropirrolo [3,4-c] pirrol
BRPI0519199A2 (pt) composiÇço de viscossuplemento e uso da mesma
BRPI0610156A2 (pt) forma micronizada de um composto, forma purificada i do composto, kit, padrão de referência, e, método de preparaçao de uma composição farmacêutica.
CR11639A (es) Compuesto (r)-n*6*-etil-6,7-dihidro-5h-indeno(5,6-d)tiazol-2,6-diamina y su uso como antipsicotico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.